[go: up one dir, main page]

BRPI0813837A2 - 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar - Google Patents

2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar

Info

Publication number
BRPI0813837A2
BRPI0813837A2 BRPI0813837-0A2A BRPI0813837A BRPI0813837A2 BR PI0813837 A2 BRPI0813837 A2 BR PI0813837A2 BR PI0813837 A BRPI0813837 A BR PI0813837A BR PI0813837 A2 BRPI0813837 A2 BR PI0813837A2
Authority
BR
Brazil
Prior art keywords
pyrolidinametanoamines
azetidinametanoamines
taar
leaders
taar leaders
Prior art date
Application number
BRPI0813837-0A2A
Other languages
English (en)
Inventor
Guido Galley
Annick Goergler
Katrin Groebke Zbinden
Roger Norcross
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0813837A2 publication Critical patent/BRPI0813837A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BRPI0813837-0A2A 2007-07-27 2008-07-18 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar BRPI0813837A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113329 2007-07-27
PCT/EP2008/059429 WO2009016048A1 (en) 2007-07-27 2008-07-18 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands

Publications (1)

Publication Number Publication Date
BRPI0813837A2 true BRPI0813837A2 (pt) 2015-01-06

Family

ID=39790251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813837-0A2A BRPI0813837A2 (pt) 2007-07-27 2008-07-18 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar

Country Status (15)

Country Link
US (2) US8389507B2 (pt)
EP (1) EP2183216A1 (pt)
JP (1) JP2010534701A (pt)
KR (1) KR101133862B1 (pt)
CN (1) CN101765587A (pt)
AR (1) AR067675A1 (pt)
AU (1) AU2008281918A1 (pt)
BR (1) BRPI0813837A2 (pt)
CA (1) CA2694362A1 (pt)
CL (1) CL2008002163A1 (pt)
PE (1) PE20090517A1 (pt)
RU (1) RU2010104632A (pt)
TW (1) TWI367094B (pt)
WO (1) WO2009016048A1 (pt)
ZA (1) ZA201000357B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
CA2954098A1 (en) * 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
CN114008021B (zh) * 2019-06-07 2024-11-05 伊莱利利公司 吡咯烷化合物
CN114426494B (zh) * 2022-01-13 2023-09-15 江苏海洋大学 一种具有作用于taar激动剂的取代甲胺类衍生物

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) 1956-01-17 Nxg hi
FR6551E (fr) 1905-07-27 1906-12-17 Carlo Chiesa Séchoir à tambour rotatif, démontable et transportable, et fonctionnant à ciel ouvert, pour cocons, céréales, etc.
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744910A (en) 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2744909A (en) 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2919274A (en) 1957-09-17 1959-12-29 Sahyun Melville Amidines
GB877306A (en) 1958-04-21 1961-09-13 Pfizer & Co C Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
DE1121054B (de) 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
DE1150180B (de) 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
US3459763A (en) 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
ES323985A1 (es) 1966-02-26 1966-12-16 Blade Pique Juan Procedimiento para la obtenciën de derivados del imidazol
FI48082C (fi) 1966-08-05 1974-06-10 Boehringer Sohn Ingelheim Menetelmä uusien verenpainetta alentavien 2-aryylihydratsino-imidatsol iinien-(2) valmistamiseksi
US3377247A (en) 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
BE754820R (fr) 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
US3818094A (en) 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3622579A (en) 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3660423A (en) 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
US4125620A (en) 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
DE3133887A1 (de) 1981-08-27 1983-03-10 Bayer Ag, 5090 Leverkusen 2-arylhydrazino-2-imidazoline, deren acylderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von endo- und ektoparasiten
ES518818A0 (es) 1982-01-27 1984-06-16 Pfizer Un procedimiento para la preparacion de una composicion ectoparasiticida, especialmente acaricida, o antihelmintica.
US4540705A (en) 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
EP0166937B1 (en) 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
US4665095A (en) 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
JPH06268356A (ja) 1993-01-18 1994-09-22 Hideaki Yamaguchi プリフラックスの使用方法およびプリント配線板の製造方法
ES2245782T3 (es) 1993-10-13 2006-01-16 H. Joseph Horacek Formula de clonidina de liberacion prolongada.
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US5610174A (en) 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5969137A (en) 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
CA2229123A1 (en) 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
RU2235092C2 (ru) 1997-12-04 2004-08-27 Оллерган Инк. Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
JP2001526286A (ja) 1997-12-19 2001-12-18 イーライ・リリー・アンド・カンパニー 低血糖性イミダゾリン化合物
WO1999054309A1 (en) 1998-04-23 1999-10-28 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
ES2150378B1 (es) 1998-08-07 2001-07-01 Esteve Labor Dr Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CA2246027A1 (en) 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
JP2001089451A (ja) * 1999-09-14 2001-04-03 Teikoku Chem Ind Corp Ltd アミノピリジン類の製造方法
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP2001302643A (ja) 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
AU2001280187A1 (en) * 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
AU2001292617A1 (en) 2000-09-12 2002-03-26 Oregon Health And Science University Mammalian receptor genes and uses
DE60113563T2 (de) 2000-11-14 2006-07-13 F. Hoffmann-La Roche Ag Substituierte 2-phenylaminoimidazolin-phenyl-ketonderivate als ip-antagonisten
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
TW200930291A (en) 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
DE102004017934A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7572921B2 (en) 2005-04-05 2009-08-11 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
EP1879455A4 (en) 2005-05-03 2011-12-28 Bayer Cropscience Ag INSECTICIDES SUBSTITUTED HETEROCYCLIC AMINOALKYL AND HETEROARYL DERIVATIVES
DE102005037733A1 (de) * 2005-08-10 2007-02-15 Merck Patent Gmbh Adeninderivate
KR20080039982A (ko) 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2c 아드레날린성 수용체 효능제로서의이미다졸 유도체
CN101312948B (zh) * 2005-09-21 2015-01-14 解码遗传Ehf公司 用于治疗炎症的lta4h的二芳基取代杂环抑制剂
DE602007005671D1 (de) 2006-10-19 2010-05-12 Hoffmann La Roche Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
CN101616902B (zh) * 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
MX2009013745A (es) 2007-07-03 2010-01-26 Hoffmann La Roche 4-imidazolinas y su uso como antidepresivos.

Also Published As

Publication number Publication date
ZA201000357B (en) 2010-09-29
KR20100039413A (ko) 2010-04-15
US20130005988A1 (en) 2013-01-03
RU2010104632A (ru) 2011-09-20
JP2010534701A (ja) 2010-11-11
US20090029962A1 (en) 2009-01-29
KR101133862B1 (ko) 2012-04-06
US8389507B2 (en) 2013-03-05
TWI367094B (en) 2012-07-01
AR067675A1 (es) 2009-10-21
TW200922555A (en) 2009-06-01
AU2008281918A1 (en) 2009-02-05
CN101765587A (zh) 2010-06-30
PE20090517A1 (es) 2009-04-29
WO2009016048A1 (en) 2009-02-05
CA2694362A1 (en) 2009-02-05
CL2008002163A1 (es) 2009-05-22
EP2183216A1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
EP2263163A4 (en) CONTENT MANAGEMENT
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BR112012001532A2 (pt) "substituída azolesulfonamides benzoimid e indolesulfonamides substituído como potenciadores mglur4"
BRPI0921327A2 (pt) Combinação de herbicida-protetor
EP2296593A4 (en) MEDICAL HEAD COVER
BRPI0918734A2 (pt) material polimérico
PL2331687T3 (pl) Środki przeciwdrobnoustrojowe
BRPI0920776A2 (pt) linha de pesca
BRPI0916551A2 (pt) dispositivo eletroquímico
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
BRPI0821652A2 (pt) tratamento de biocombustíveis
DK2155273T3 (da) Lugtregulerende genstand
LT3150178T (lt) Stimuliavimo aparatas
FI9107U1 (fi) Houkutin
BRPI0922728A2 (pt) combinação de herbicida-antídoto
EP2298116A4 (en) COMB
HRP20160577T1 (hr) Liječenje osteoartritisa
FR2940007B1 (fr) Taille-haie
BRPI0916990A2 (pt) Combinações inseticidas
BRPI0912324A2 (pt) distribuição de observação
FI20085395A0 (fi) Ilmanvaihtokanava
BRPI0813837A2 (pt) 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar
DE112009003312A5 (de) Implantat

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.